Active, not recruitingPhase 1NCT05312411

A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

Studying Osteosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Seattle Children's Hospital
Principal Investigator
Catherine Albert, MD
Seattle Children's Hospital
Intervention
SCRI-E2CAR_EGFRtv1(biological)
Enrollment
21 enrolled
Eligibility
15-30 years · All sexes
Timeline
20222040

Study locations (1)

Collaborators

Umoja Biopharma

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05312411 on ClinicalTrials.gov

Other trials for Osteosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Osteosarcoma

← Back to all trials